{"id":"nabilone-oral-capsule","safety":{"commonSideEffects":[{"rate":"20-30","effect":"Dizziness"},{"rate":"15-25","effect":"Drowsiness"},{"rate":"10-20","effect":"Dry mouth"},{"rate":"5-15","effect":"Euphoria"},{"rate":"5-10","effect":"Ataxia"},{"rate":"5-10","effect":"Vertigo"},{"rate":"5-10","effect":"Concentration difficulty"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Nabilone acts as a partial agonist at CB1 and CB2 cannabinoid receptors, which are involved in regulating nausea, vomiting, and pain perception. By activating these receptors, it suppresses the vomiting center and modulates pain signaling pathways. It is structurally similar to delta-9-tetrahydrocannabinol (THC) but is a fully synthetic compound with more predictable pharmacokinetics.","oneSentence":"Nabilone is a synthetic cannabinoid that mimics THC by binding to cannabinoid receptors in the central nervous system to produce antiemetic and analgesic effects.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:56:28.908Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Chemotherapy-induced nausea and vomiting (CINV)"},{"name":"Chronic pain"},{"name":"Multiple sclerosis-related spasticity"}]},"trialDetails":[{"nctId":"NCT05885685","phase":"PHASE4","title":"Investigating the Effects of Nabilone on Endocannabinoid Metabolism","status":"COMPLETED","sponsor":"Centre for Addiction and Mental Health","startDate":"2023-10-31","conditions":"Healthy","enrollment":10},{"nctId":"NCT05742698","phase":"PHASE2","title":"Nabilone for Agitation in Frontotemporal Dementia","status":"RECRUITING","sponsor":"Simon Ducharme, MD","startDate":"2023-03-07","conditions":"Frontotemporal Dementia, Frontotemporal Dementia, Behavioral Variant, Primary Progressive Aphasia","enrollment":45},{"nctId":"NCT04880278","phase":"PHASE1, PHASE2","title":"Multimodal Assessment of Cannabinoid Target Engagement in Adults With Obsessive-Compulsive Disorder","status":"WITHDRAWN","sponsor":"New York State Psychiatric Institute","startDate":"2022-03-01","conditions":"Obsessive-Compulsive Disorder","enrollment":""},{"nctId":"NCT04801641","phase":"PHASE2","title":"A Pilot Trial of Nabilone for the Treatment of Obesity","status":"TERMINATED","sponsor":"Centre for Addiction and Mental Health","startDate":"2021-09-17","conditions":"Obesity","enrollment":24},{"nctId":"NCT05180968","phase":"PHASE3","title":"DIalysis Symptom COntrol-Pruritus Outcome Trial","status":"COMPLETED","sponsor":"University of Manitoba","startDate":"2022-08-02","conditions":"End Stage Renal Disease, Pruritus","enrollment":14},{"nctId":"NCT03422861","phase":"NA","title":"Nabilone Use For Acute Pain in Inflammatory Bowel Disease Patients","status":"UNKNOWN","sponsor":"Samuel Lunenfeld Research Institute, Mount Sinai Hospital","startDate":"2023-12","conditions":"Inflammatory Bowel Diseases","enrollment":80},{"nctId":"NCT03769896","phase":"PHASE2","title":"Nabilone for Non-motor Symptoms in Parkinson's Disease","status":"COMPLETED","sponsor":"Medical University Innsbruck","startDate":"2017-10-03","conditions":"Parkinson Disease","enrollment":48},{"nctId":"NCT03773796","phase":"PHASE3","title":"Nabilone for Non-motor Symptoms in Parkinson's Disease","status":"COMPLETED","sponsor":"Medical University Innsbruck","startDate":"2018-08-06","conditions":"Parkinson Disease","enrollment":22},{"nctId":"NCT01347762","phase":"PHASE2, PHASE3","title":"Nabilone for Cannabis Dependence: A Pilot Study","status":"COMPLETED","sponsor":"Mclean Hospital","startDate":"2010-06","conditions":"Cannabis Dependence, Marijuana Dependence","enrollment":84},{"nctId":"NCT02802540","phase":"PHASE2, PHASE3","title":"Nabilone Effect on the Attenuation of Anorexia, Nutritional Status and Quality of Life in Lung Cancer Patients","status":"UNKNOWN","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2014-12","conditions":"Non-Small Cell Lung Cancer, Anorexia, Cachexia","enrollment":78}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["TEVA-nabilone","TEVA-Nabilone Placebo"],"phase":"marketed","status":"active","brandName":"Nabilone Oral Capsule","genericName":"Nabilone Oral Capsule","companyName":"Centre for Addiction and Mental Health","companyId":"centre-for-addiction-and-mental-health","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Nabilone is a synthetic cannabinoid that mimics THC by binding to cannabinoid receptors in the central nervous system to produce antiemetic and analgesic effects. Used for Chemotherapy-induced nausea and vomiting (CINV), Chronic pain, Multiple sclerosis-related spasticity.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}